Mounjaro (with a main active ingredient of tirzepatide) is a medication designed to help with blood sugar management in people with type 2 diabetes. It’s a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist and is the first medication in the GIP/GLP-1 receptor agonist drug class, per the FDA.
Mounjaro (Tirzepatide) works similarly to Ozempic (Semaglutide), but also targets GIP receptors, in addition to GLP-1 receptors.
According to research, someone may have better results on Mounjaro if Ozempic didnt help them reach their goals because it targets an additional receptor.